Henlius

Henlius

Biotechnology, Milmont Dr Ste 107c, shanghai, , 94538, California, 48860, United States, 1001-5000 Employees

henlius.com/en/index.html

  • LinkedIn

phone no Phone Number: +15*********

Who is HENLIUS

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncolog...

Read More

map
  • 48860 Milmont Dr Ste 107c, shanghai, California, 94538, United States Headquarters: 48860 Milmont Dr Ste 107c, shanghai, California, 94538, United States
  • 2010 Date Founded: 2010
  • 1001-5000 Employees: 1001-5000
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731 | NAICS Code: 541715 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from HENLIUS

Henlius Org Chart and Mapping

Employees

Leon T

Senior Director of Business Development, in-Licensing

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Henlius

Answer: Henlius's headquarters are located at Milmont Dr Ste 107c, shanghai, , 94538, California, 48860, United States

Answer: Henlius's phone number is +15*********

Answer: Henlius's official website is https://henlius.com/en/index.html

Answer: Henlius's revenue is $5 Million to $10 Million

Answer: Henlius's SIC: 8731

Answer: Henlius's NAICS: 541715

Answer: Henlius has 1001-5000 employees

Answer: Henlius is in Biotechnology

Answer: Henlius contact info: Phone number: +15********* Website: https://henlius.com/en/index.html

Answer: Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Up to date, 5 products have been launched in China, 2 has been approved for marketing in overseas markets, 19 indications are approved worldwide, and 3 marketing applications have been accepted for review in China, the U.S. and EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation center and Shanghai-based manufacturing facilities in line with global Good Manufacturing Practice (GMP), including Xuhui Plant certificated by China and the EU GMP and Songjiang First Plant certificated by China GMP. Henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies (mAbs) and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as backbone. Apart from the launched products HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab for injection, trade name in Europe: Zercepac; trade names in Australia: Tuzucip and Trastucip, the first China-developed mAb biosimilar approved both in China and Europe, HANDAYUAN (adalimumab) and HANBEITAI (bevacizumab), HANSIZHUANG has been approved by the NMPA for the treatment of MSI-H solid tumors, sqNSCLC, ES-SCLC, and ESCC, making it the worlds first anti-PD-1 mAb for the first-line treatment of SCLC. Its NDA for the treatment of nsNSCLC is under review. What's more, Henlius has conduct over 30 clinical studies for 16 products globally, expanding its presence in major markets as well as emerging markets.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access